Seminars in Hematology
Volume 44, Issue 3 , Pages 193-202 , July 2007

Hematopoietic Growth Factors for Hematopoietic Stem Cell Mobilization and Expansion

  • Robert Möhle

      Affiliations

    • Corresponding Author InformationAddress correspondence to Robert Möhle, MD, Department of Medicine II, University of Tübingen, Otfried-Müller-Str 10, 72076 Tübingen, Germany.
    • ,
  • Lothar Kanz

References 

  1. Zsebo KM, Yuschenkoff VN, Schiffer S, Chang D, McCall E, Dinarello CA, et al. Vascular endothelial cells and granulopoiesis: interleukin-1 stimulates release of G-CSF and GM-CSF. Blood. 1988;71:99–103
  2. Fibbe WE, van Damme J, Billiau A, Voogt PJ, Duinkerken N, Kluck PM, et al. Interleukin-1 (22-K factor) induces release of granulocyte-macrophage colony-stimulating activity from human mononuclear phagocytes. Blood. 1986;68:1316–1321
  3. Fibbe WE, van Damme J, Billiau A, Goselink HM, Voogt PJ, van Eeden G, et al. Interleukin 1 induces human marrow stromal cells in long-term culture to produce granulocyte colony-stimulating factor and macrophage colony-stimulating factor. Blood. 1988;71:430–435
  4. Soderquist B, Kallman J, Holmberg H, Vikerfors T, Kihlstrom E. Secretion of IL-6, IL-8 and G-CSF by human endothelial cells in vitro in response to Staphylococcus aureus and staphylococcal exotoxins. APMIS. 1998;106:1157–1164
  5. Kawakami M, Tsutsumi H, Kumakawa T, Abe H, Hirai M, Kurosawa S, et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood. 1990;76:1962–1964
  6. Watari K, Asano S, Shirafuji N, Kodo H, Ozawa K, Takaku F, et al. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood. 1989;73:117–122
  7. Haas R, Gericke G, Witt B, Cayeux S, Hunstein W. Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation. Exp Hematol. 1993;21:109–113
  8. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068–4071
  9. Bodine DM, Seidel NE, Orlic D. Bone marrow collected 14 days after in vivo administration of granulocyte colony-stimulating factor and stem cell factor to mice has 10-fold more repopulating ability than untreated bone marrow. Blood. 1996;88:89–97
  10. McCredie KB, Hersh EM, Freireich EJ. Cells capable of colony formation in the peripheral blood of man. Science. 1971;171:293–294
  11. Hershko C, Gale RP, Ho WG, Cline MJ. Cure of aplastic anaemia in paroxysmal nocturnal haemoglobinuria by marrow transfusion from identical twin: Failure of peripheral-leukocyte transfusion to correct marrow aplasia. Lancet. 1979;1:945–947
  12. Abrams RA, Glaubiger D, Appelbaum FR, Deisseroth AB. Result of attempted hematopoietic reconstitution using isologous, peripheral blood mononuclear cells: A case report. Blood. 1980;56:516–520
  13. Rich KC, Richman CM, Mejias E, Daddona P. Immunoreconstitution by peripheral blood leukocytes in adenosine deaminase-deficient severe combined immunodeficiency. J Clin Invest. 1980;66:389–395
  14. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood. 1976;47:1031–1039
  15. Abrams RA, McCormack K, Bowles C, Deisseroth AB. Cyclophosphamide treatment expands the circulating hematopoietic stem cell pool in dogs. J Clin Invest. 1981;67:1392–1399
  16. To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp DL, et al. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol. 1990;18:442–447
  17. Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci U S A. 1985;82:1526–1530
  18. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, et al. Recombinant human granulocyte colony-stimulating factor: Effects on normal and leukemic myeloid cells. Science. 1986;232:61–65
  19. Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987;56:809–813
  20. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988;318:1414–1422
  21. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988;72:2074–2081
  22. Lapidot T, Petit I. Current understanding of stem cell mobilization: The roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002;30:973–981
  23. Valenzuela-Fernandez A, Planchenault T, Baleux F, Staropoli I, Le Barillec K, Leduc D, et al. Leukocyte elastase negatively regulates Stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4. J Biol Chem. 2002;277:15677–15689
  24. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood. 2001;98:1289–1297
  25. Christopherson KW, Cooper S, Broxmeyer HE. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood. 2003;101:4680–4686
  26. Sheridan WP, Begley CG, Juttner CA, Szer J, To LB, Maher D, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet. 1992;339:640–644
  27. Mohle R, Pforsich M, Fruehauf S, Witt B, Kramer A, Haas R. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis. Bone Marrow Transplant. 1994;14:827–832
  28. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al Olama A, Keating C, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood. 2001;98:2059–2064
  29. Engelhardt M, Bertz H, Afting M, Waller CF, Finke J. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol. 1999;17:2160–2172
  30. Engelhardt M, Bertz H, Wasch R, Finke J. Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation. Ann Hematol. 2001;80:201–208
  31. Dunn CJ, Goa KL. Lenograstim: An update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs. 2000;59:681–717
  32. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353–357
  33. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D, et al: Stem cell mobilization. Hematology (Am Soc Hematol Educ Program) 419-437, 2003
  34. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18:2522–2528
  35. Kroschinsky F, Holig K, Poppe-Thiede K, Zimmer K, Ordemann R, Blechschmidt M, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica. 2005;90:1665–1671
  36. Malerba L, Mele A, Leopardi G, Stramigioli S, Politi P, Visani G. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient. Eur J Haematol. 2006;76:436–439
  37. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol. 2000;18:43–53
  38. Weaver CH, Schulman KA, Buckner CD. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant. 2001;27(Suppl 2):S23–S29
  39. Gazitt Y, Callander N, Freytes CO, Shaughnessy P, Liu Q, Tsai TW, et al. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin’s lymphoma patients: A randomized prospective study. J Hematother Stem Cell Res. 2000;9:737–748
  40. Ballestrero A, Ferrando F, Garuti A, Basta P, Gonella R, Stura P, et al. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF. J Clin Oncol. 1999;17:1296
  41. Sohn SK, Kim JG, Seo KW, Chae YS, Jung JT, Suh JS, et al. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2002;30:81–86
  42. Lane TA, Ho AD, Bashey A, Peterson S, Young D, Law P. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transfusion. 1999;39:39–47
  43. Perillo A, Pierelli L, Scambia G, Serafini R, Paladini U, Salerno MG, et al. Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: A randomized comparison of G-CSF and sequential GM-/G-CSF. Transfusion. 2001;41:674–680
  44. Comenzo RL, Sanchorawala V, Fisher C, Akpek G, Farhat M, Cerda S, et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol. 1999;104:553–559
  45. Koc ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, et al. Randomized cross-over trial of progenitor-cell mobilization: High-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol. 2000;18:1824–1830
  46. Shaughnessy PJ, Bachier C, Lemaistre CF, Akay C, Pollock BH, Gazitt Y. Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors. Stem Cells. 2006;24:1789–1797
  47. Lonial S, Hicks M, Rosenthal H, Langston A, Redei I, Torre C, et al. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant. 2004;10:848–857
  48. D’Hondt V, Guillaume T, Humblet Y, Doyen C, Chatelain B, Feyens AM, et al. Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: A pilot study. Bone Marrow Transplant. 1994;13:261–264
  49. Rosenfeld CS, Bolwell B, LeFever A, Taylor R, List A, Fay J, et al. Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF. Bone Marrow Transplant. 1996;17:179–183
  50. Brugger W, Bross K, Frisch J, Dern P, Weber B, Mertelsmann R, et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood. 1992;79:1193–1200
  51. Haas R, Ehrhardt R, Witt B, Goldschmidt H, Hohaus S, Pforsich M, et al. Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1993;12:643–649
  52. Bishop MR, Jackson JD, O’Kane-Murphy B, Schmit-Pokorny K, Vose JM, Bierman PJ, et al. Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells. J Clin Oncol. 1996;14:2521–2526
  53. Miller LL, Korn EL, Stevens DS, Janik JE, Gause BL, Kopp WC, et al. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood. 1999;93:3250–3258
  54. Glaspy JA, Shpall EJ, Lemaistre CF, Briddell RA, Menchaca DM, Turner SA, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood. 1997;90:2939–2951
  55. Basser RL, To LB, Begley CG, Maher D, Juttner C, Cebon J, et al. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: Enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor. J Clin Oncol. 1998;16:1899–1908
  56. Weaver A, Chang J, Wrigley E, de Wynter E, Woll PJ, Lind M, et al. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. J Clin Oncol. 1998;16:2601–2612
  57. Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood. 1999;93:2491–2501
  58. To LB, Bashford J, Durrant S, MacMillan J, Schwarer AP, Prince HM, et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant. 2003;31:371–378
  59. Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin’s lymphoma patients—Results of a phase I/II trial. Blood. 1997;89:3136–3147
  60. Dawson MA, Schwarer AP, Muirhead JL, Bailey MJ, Bollard GM, Spencer A. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen. Bone Marrow Transplant. 2005;36:389–396
  61. Stachel DK, Leipold A, Krapf T, Knufer V, Ringwald J, Strasser E, et al. Successful stem cell mobilization with stem cell factor and granulocyte colony-stimulating factor in patients with solid tumors failing conventional mobilization with chemotherapy and G-CSF. J Hematother Stem Cell Res. 2003;12:131–133
  62. Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106:1867–1874
  63. Molineux G, McCrea C, Yan XQ, Kerzic P, McNiece I. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood. 1997;89:3998–4004
  64. Juan TS, McNiece IK, Van G, Lacey D, Hartley C, McElroy P, et al. Chronic expression of murine flt3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis. Blood. 1997;90:76–84
  65. Pierelli L, Perillo A, Greggi S, Salerno G, Panici PB, Menichella G, et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: Results of a randomized comparison. J Clin Oncol. 1999;17:1288
  66. Waller CF, von Lintig F, Daskalakis A, Musahl V, Lange W. Mobilization of peripheral blood progenitor cells in patients with breast cancer: A prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Bone Marrow Transplant. 1999;24:19–24
  67. Linker C, Anderlini P, Herzig R, Christiansen N, Somlo G, Bensinger W, et al. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant. 2003;9:405–413
  68. Iscove NN, Nawa K. Hematopoietic stem cells expand during serial transplantation in vivo without apparent exhaustion. Curr Biol. 1997;7:805–808
  69. Brandt J, Briddell RA, Srour EF, Leemhuis TB, Hoffman R. Role of c-kit ligand in the expansion of human hematopoietic progenitor cells. Blood. 1992;79:634–641
  70. Srour EF, Brandt JE, Briddell RA, Grigsby S, Leemhuis T, Hoffman R. Long-term generation and expansion of human primitive hematopoietic progenitor cells in vitro. Blood. 1993;81:661–669
  71. Brugger W, Mocklin W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood. 1993;81:2579–2584
  72. Shapiro F, Yao TJ, Raptis G, Reich L, Norton L, Moore MA. Optimization of conditions for ex vivo expansion of CD34+ cells from patients with stage IV breast cancer. Blood. 1994;84:3567–3574
  73. Zijlmans JM, Visser JW, Laterveer L, Kleiverda K, Heemskerk DP, Kluin PM, et al. The early phase of engraftment after murine blood cell transplantation is mediated by hematopoietic stem cells. Proc Natl Acad Sci U S A. 1998;95:725–729
  74. Dorrell C, Gan OI, Pereira DS, Hawley RG, Dick JE. Expansion of human cord blood CD34(+)CD38(−) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. Blood. 2000;95:102–110
  75. Petzer AL, Zandstra PW, Piret JM, Eaves CJ. Differential cytokine effects on primitive (CD34+CD38−) human hematopoietic cells: Novel responses to Flt3-ligand and thrombopoietin. J Exp Med. 1996;183:2551–2558
  76. Yonemura Y, Ku H, Lyman SD, Ogawa M. In vitro expansion of hematopoietic progenitors and maintenance of stem cells: Comparison between FLT3/FLK-2 ligand and KIT ligand. Blood. 1997;89:1915–1921
  77. Lu M, Zhang N, Maruyama M, Hawley RG, Ho AD. Retrovirus-mediated gene expression in hematopoietic cells correlates inversely with growth factor stimulation. Hum Gene Ther. 1996;7:2263–2271
  78. Yonemura Y, Ku H, Hirayama F, Souza LM, Ogawa M. Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells. Proc Natl Acad Sci U S A. 1996;93:4040–4044
  79. Bryder D, Jacobsen SE. Interleukin-3 supports expansion of long-term multilineage repopulating activity after multiple stem cell divisions in vitro. Blood. 2000;96:1748–1755
  80. Conneally E, Cashman J, Petzer A, Eaves C. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc Natl Acad Sci U S A. 1997;94:9836–9841
  81. Piacibello W, Sanavio F, Severino A, Dane A, Gammaitoni L, Fagioli F, et al. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood. 1999;93:3736–3749
  82. Jacobsen SE, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. J Exp Med. 1995;181:1357–1363
  83. Petzer AL, Hogge DE, Landsdorp PM, Reid DS, Eaves CJ. Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci U S A. 1996;93:1470–1474
  84. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568–571
  85. Ku H, Yonemura Y, Kaushansky K, Ogawa M. Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood. 1996;87:4544–4551
  86. Sitnicka E, Lin N, Priestley GV, Fox N, Broudy VC, Wolf NS, et al. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood. 1996;87:4998–5005
  87. Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood. 1996;88:429–436
  88. Kobayashi M, Imamura M, Gotohda Y, Maeda S, Iwasaki H, Sakurada K, et al. Synergistic effects of interleukin-1 beta and interleukin-3 on the expansion of human hematopoietic progenitor cells in liquid cultures. Blood. 1991;78:1947–1953
  89. Bertolini F, Soligo D, Lazzari L, Corsini C, Servida F, Sirchia G. The effect of interleukin-12 in ex-vivo expansion of human haemopoietic progenitors. Br J Haematol. 1995;90:935–938
  90. Kollet O, Aviram R, Chebath J, Ben Hur H, Nagler A, Shultz L, et al. The soluble interleukin-6 (IL-6) receptor/IL-6 fusion protein enhances in vitro maintenance and proliferation of human CD34(+)CD38(−/low) cells capable of repopulating severe combined immunodeficiency mice. Blood. 1999;94:923–931
  91. Henschler R, Brugger W, Luft T, Frey T, Mertelsmann R, Kanz L. Maintenance of transplantation potential in ex vivo expanded CD34(+)-selected human peripheral blood progenitor cells. Blood. 1994;84:2898–2903
  92. Peters SO, Kittler EL, Ramshaw HS, Quesenberry PJ. Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood. 1996;87:30–37
  93. Tisdale JF, Hanazono Y, Sellers SE, Agricola BA, Metzger ME, Donahue RE, et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood. 1998;92:1131–1141
  94. Guenechea G, Segovia JC, Albella B, Lamana M, Ramirez M, Regidor C, et al. Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord blood cells. Blood. 1999;93:1097–1105
  95. McNiece IK, Almeida-Porada G, Shpall EJ, Zanjani E. Ex vivo expanded cord blood cells provide rapid engraftment in fetal sheep but lack long-term engrafting potential. Exp Hematol. 2002;30:612–616
  96. Reiffers J, Cailliot C, Dazey B, Attal M, Caraux J, Boiron JM. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet. 1999;354:1092–1093
  97. Boiron JM, Dazey B, Cailliot C, Launay B, Attal M, Mazurier F, et al. Large-scale expansion and transplantation of CD34(+) hematopoietic cells: In vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity. Transfusion. 2006;46:1934–1942
  98. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant. 2002;8:368–376
  99. Jaroscak J, Goltry K, Smith A, Waters-Pick B, Martin PL, Driscoll TA, et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: Results of a phase 1 trial using the AastromReplicell System. Blood. 2003;101:5061–5067
  100. Haylock DN, Makino S, Dowse TL, Trimboli S, Niutta S, To LB, et al. Ex vivo hematopoietic progenitor cell expansion. Immunomethods. 1994;5:217–225
  101. Williams SF, Lee WJ, Bender JG, Zimmerman T, Swinney P, Blake M, et al. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. Blood. 1996;87:1687–1691
  102. Alcorn MJ, Holyoake TL, Richmond L, Pearson C, Farrell E, Kyle B, et al. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol. 1996;14:1839–1847
  103. Bachier CR, Gokmen E, Teale J, Lanzkron S, Childs C, Franklin W, et al. Ex-vivo expansion of bone marrow progenitor cells for hematopoietic reconstitution following high-dose chemotherapy for breast cancer. Exp Hematol. 1999;27:615–623
  104. McNiece I, Jones R, Bearman SI, Cagnoni P, Nieto Y, Franklin W, et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood. 2000;96:3001–3007
  105. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, et al. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood. 2000;96:2385–2390
  106. Stiff P, Chen B, Franklin W, Oldenberg D, Hsi E, Bayer R, et al. Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer. Blood. 2000;95:2169–2174
  107. Prince HM, Simmons PJ, Whitty G, Wall DP, Barber L, Toner GC, et al. Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells. Br J Haematol. 2004;126:536–545

PII: S0037-1963(07)00069-8

doi: 10.1053/j.seminhematol.2007.04.006

Seminars in Hematology
Volume 44, Issue 3 , Pages 193-202 , July 2007

Article Tools